Abbott India ABBOTINDIA
Indian listed arm of Abbott Laboratories selling branded formulations (Thyronorm, Duphaston, Udiliv, Digene) - a pure domestic play
Mapped in 1 theme: Pharmaceuticals.
Where Abbott India sits in the supply chain
Abbott India appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 5,849 | 6,409 | 6,929 |
| Net profit | 1,201 | 1,414 | 1,552 |
Latest-year revenue ₹6,929 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Very high returns on capital with no debt and a healthy dividend yield
- 100% domestic - insulated from US pricing, tariffs and USFDA risk
- Strong women's health, thyroid and GI brands with parent's global pipeline to in-license
Risks
- Slow growth for a premium valuation - revenue CAGR ~9% FY22-FY26
- Relies heavily on contract manufacturers and on the parent for new products
- Exposure to NLEM price caps on several key brands
Common questions
What does Abbott India do?
Indian listed arm of Abbott Laboratories selling branded formulations (Thyronorm, Duphaston, Udiliv, Digene) - a pure domestic play.
Where does Abbott India sit in the supply chain?
Abbott India (NSE: ABBOTINDIA) is mapped in 1 supply-chain layer: India branded formulations (Pharmaceuticals).
Who are Abbott India's peers?
In the India branded formulations layer of Pharmaceuticals: Sun Pharmaceutical Industries, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Eris Lifesciences, Cipla and 4 more.
What is Abbott India's market cap and valuation?
As of 30 Oct 2026: market cap ₹54,552 Cr, P/E 33.8x, ROCE 44.8%, ROE 34.4%, dividend yield 2.05%.